Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors
February 10 2017 - 5:00PM
Osiris Therapeutics, Inc. (NASDAQ:OSIR) is pleased to announce that
its Board of Directors, at a Board Meeting on February 7th, 2017,
confirmed the appointment of Messrs. Uwe Sommer and Thomas J. Knapp
as Directors, upon recommendation of the Nominating Committee, and
each will stand for election at the Company’s 2017 Stockholders’
Meeting. Mr. Sommer and Mr. Knapp each join Osiris as
independent Board members.
“We are pleased to have Mr. Sommer and Mr. Knapp join Osiris at
this important time,” said Peter Friedli, Chairman of the Board.
“Both gentlemen have extensive and diverse business experience, and
their contributions will be greatly appreciated.”
Mr. Sommer is a highly experienced leader in global marketing
and sales, managing distribution in markets including Europe,
Japan, the Middle East, Africa, and the United States. Mr.
Sommer has held executive roles with Johnson & Johnson, Lindt
& Sprüngli, Mars, Inc., and Procter & Gamble. Mr.
Sommer has degrees in Economics from University Kiel (Germany) and
Marketing and Economics from Penn State University.
Mr. Knapp has over 25 years of corporate and large legal firm
experience with regulated industries, with experience including
Federal and State regulatory matters, Federal government affairs,
risk management, compliance, litigation, complex commercial
transactions, and corporate governance. Mr. Knapp is
presently Interim General Counsel and Corporate Secretary with
Galena Biopharma, Inc., prior to which his experience includes
serving as EVP, Chief Legal Officer, and Corporate Secretary of
Sucampo Pharmaceuticals, Inc., as Vice President, General Counsel
and Corporate Secretary at NorthWestern Corporation, and in senior
in-house attorney positions at The Boeing Company and The
Burlington Northern & Santa Fe Railway Company.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a
leader in researching, developing and marketing cellular
regenerative medicine products that improve the health and lives of
patients and lower overall healthcare costs. Having developed
the world’s first approved stem cell drug, Osiris works to further
advance the medical field. Osiris’ research and development
in biotechnology focuses on innovation in regenerative medicine –
including bioengineering, stem cell research and viable tissue
based products. Osiris has achieved commercial success with
products in orthopaedics, sports medicine and wound care, including
BIO4®, a viable bone matrix, Cartiform®, a viable osteochondral
allograft, Grafix®, a cryopreserved placental membrane, and
Stravix®, a durable placental allograft. Osiris, Grafix,
Cartiform, and Stravix are trademarks of Osiris Therapeutics, Inc.
BIO4 is a registered trademark of Howmedica Osteonics
Corp. More information can be found on the company's website,
www.osiris.com. (OSIR-G)
For additional information, please contact:
Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1839
OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Apr 2023 to Apr 2024